Parallel Advisors’s Exagen XGN Stock Holding History

Parallel Advisors’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,213	Closed	-$11K	–	3533
2022 Q3	$11K	Hold	4,213	–	–	﹤0.01%	1978
2022 Q2	$24K	Hold	4,213	–	–	﹤0.01%	1590
2022 Q1	$34K	Sell	4,213 -112	-3%	-$966	﹤0.01%	1474
2021 Q4	$50K	Hold	4,325	–	–	﹤0.01%	1320
2021 Q3	$59K	Hold	4,325	–	–	﹤0.01%	1211
2021 Q2	$65K	Hold	4,325	–	–	﹤0.01%	1123
2021 Q1	$76K	Buy	+4,325	New	+$77.1K	﹤0.01%	998

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Parallel Advisors's XGN Position: Q4 2022 in Review

Parallel Advisors sold out of Exagen (XGN) in Q4 2022, closing a stake of 4,213 shares — an estimated $11K sold.

Parallel Advisors first reported a position in XGN in Q1 2021 and held it in 7 quarters. The position peaked at $76K in Q1 2021. 31 funds tracked by Wall St. Rank hold XGN as of Q4 2022.

Parallel Advisors reported no remaining Exagen position as of Q4 2022 after selling out during the quarter.
Parallel Advisors sold 4,213 Exagen shares in Q4 2022, an estimated $11K.
Parallel Advisors first reported a position in Exagen in Q1 2021 and held it in 7 quarters.
Parallel Advisors's Exagen position peaked at $76K in Q1 2021.
31 funds tracked by Wall St. Rank held Exagen as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.